StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) stock

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$11.79−0.41 (-3.36%)

Close on Nov 18, 2026Market cap $1.53BP/E –Yield –

Kailera Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$133.67M–
Q2 FY2026Jun 30, 2026-$77.53M–
Q1 FY2026Mar 31, 2026-$68.31M–
Q3 FY2025Sep 30, 2025-$29.70M–
Q2 FY2025Jun 30, 2025-$26.23M–
Q1 FY2025Mar 31, 2025-$18.20M–

More Kailera Therapeutics figures

See a number that looks wrong?